Gold bars to be exempt from tariffs, White House clarifies
AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), the Cambridge, UK-based global biopharmaceutical company with a market capitalization of $230 billion, today announced the publication of its 2024 Annual Report and Form 20-F. The document, which provides a comprehensive overview of the company’s financial performance and operations, including its impressive $54 billion in revenue, will be available for inspection on the National Storage Mechanism and can also be accessed via the company’s website. According to InvestingPro analysis, AstraZeneca (NASDAQ:AZN) maintains a "GREAT" financial health score, reflecting its strong market position.
The report outlines the principal risks and uncertainties faced by the company, as well as the directors’ responsibility statement concerning the financial statements and directors’ report. Additionally, it includes a statement regarding related party transactions. InvestingPro data reveals that AstraZeneca has maintained dividend payments for 33 consecutive years, demonstrating consistent shareholder returns despite market uncertainties.
The Annual General Meeting (AGM) for AstraZeneca is scheduled to take place on April 11, 2025. Shareholders will receive the Notice of AGM and Shareholders’ Circular in due course, detailing the agenda and proposals to be discussed and voted upon. With the company currently trading below its Fair Value according to InvestingPro analysis, investors may find particular interest in the upcoming meeting’s strategic discussions.
AstraZeneca specializes in the discovery, development, and commercialization of prescription medicines across various therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals. The company’s products are available in over 125 countries and are used by millions of patients worldwide. With an impressive gross profit margin of 82% and strong revenue growth of 18% in the last twelve months, AstraZeneca continues to demonstrate its market leadership.
Investors and media representatives seeking further information are directed to contact AstraZeneca’s Investor Relations and Media teams through the channels provided on the company’s website.
The filing of the annual report adheres to the requirements of the Securities Exchange Act of 1934 and was duly signed by Adrian Kemp, Company Secretary of AstraZeneca PLC, as of today.
This article is based on a press release statement.
In other recent news, AstraZeneca has announced significant changes to its board of directors. Karen Knudsen is set to join as a Non-Executive Director, while current Non-Executive Directors Deborah DiSanzo and Andreas Rummelt will retire. Diana Layfield, another Non-Executive Director, has been appointed to the Remuneration Committee.
In the realm of financial analysis, UBS has upgraded AstraZeneca’s stock rating from Neutral to Buy and raised the price target to GBP142.00. This optimistic outlook is based on the company’s strong standing within the global Major Pharma sector and robust sales growth projections up to the year 2029. UBS anticipates a compound annual growth rate of 6% in revenue from 2024 to 2030, potentially elevating total revenue to $74.4 billion.
Bank of America Securities has maintained its Buy rating on AstraZeneca stock with a steady price target of GBP145.00. The firm’s positive stance is based on the pharmaceutical giant’s valuation and anticipated mid-term guidance suggesting a high-single digit sales compound annual growth rate. AstraZeneca is expected to encounter significant developments in the next 18 months, with multiple pivotal trial results anticipated.
Morgan Stanley (NYSE:MS) has given AstraZeneca an Overweight rating with a price target of GBP145.00. The firm’s positive outlook is bolstered by AstraZeneca’s strong product sales momentum, particularly from drugs like Imfinzi, Teszpire, and Enhertu. Morgan Stanley also sees potential for additional upside from a prospective partnership agreement and anticipates several significant pipeline readouts.
Finally, Goldman Sachs has updated its price target on AstraZeneca shares to GBP150.67, down from GBP155.58, while reaffirming a Buy rating on the stock. The firm expressed continued confidence in AstraZeneca, citing a robust pipeline of products and the company’s ambitious revenue goal of $80 billion by 2030. Despite challenges in China, Goldman Sachs does not see them as a significant deterrent to AstraZeneca’s stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.